CGEM
Published on 05/08/2025 at 07:00, updated on 05/08/2025 at 09:07
Cullinan Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 48.5 million compared to USD 37.15 million a year ago. Basic loss per share from continuing operations was USD 0.74 compared to USD 0.75 a year ago.
Diluted loss per share from continuing operations was USD 0.74 compared to USD 0.75 a year ago.